Shares of Vertex Pharmaceuticals (VRTX) were climbing by 22.86% to $161.19 in after hours trading on Tuesday afternoon, after the bio therapeutic drug company said it has seen positive data from its Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis.
Cystic fibrosis is an inherited disorder that causes damage to the lungs, digestive system, and other organs of the body, Moya Clinic explains. The disease impacts the cells that produce mucus, sweat, and digestive fluids.
"These safety and efficacy data are clear and compelling, indicating significant potential benefit for people with CF from each of these three different triple combination regimens," Vertex Chief Medical Officer Jeffrey Chodakewitz said.
Vertex is going to continue to evaluate the data and decide on which regimens it will take forward into key programs in the first half of next year.